Clinical Trials
- Leukemia, Supportive Care
Early HLA Matched Sibling Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: A Sickle Transplant Alliance for Research (STAR) Trial
- Lung Cancer, Pediatric Cancers
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment (HEART)
- Ages18 years and older
- GenderBoth
- Leukemia, Pediatric Cancers, Non-Therapeutic, Sickle Cell Disorders
Identifying Predictors of Poor Health-Related Quality-of-Life Among Pediatric Hematopoietic Stem Cell Donors
- Leukemia, Pediatric Cancers
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
- Lymphoma, Leukemia
Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
- Immune System, Infectious Disease
Multicenter, Open Label, Phase 3 Trial of ATA129 for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
- GenderBoth
- Liver Cancer
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
- Sarcoma Cancers, Kidney Cancer, Pediatric Cancers
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumors
- Pediatric Cancers
PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib
- Brain and Other Nervous System Cancers, Pediatric Cancers
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
- Ages1 year 5 months and younger
- GenderBoth